Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon

• US 5,028,422 A
• Filed: 04/13/1989
• Issued: 07/02/1991
• Est. Priority Date: 05/27/1986
• Status: Expired due to Fees

• Current Assignee: Schering Corporation (Merck & Co., Inc.)
• Original Assignee: Schering Corporation (Merck & Co., Inc.)
• Inventors: Smiles, Kenneth A., Tanner, Daniel J., Peets, Edwin A.
• Primary Examiner(s): Moezie, F. T.
• Assistant Examiner(s): ROZYCKI, ANDREW
• Application Number:
  US07/337,586
• Time in Patent Office: 810 Days
• Field of Search: 424/85.7, 424/85.4
• US Class Current: 424/85.4
• CPC Class Codes: A61K 38/212 IFN-alpha

Abstract

This invention relates to a method of treating basal cell carcinoma with purified human recombinant DNA interferon alpha-2, preferably purified human recombinant DNA interferon alpha-2b by administering intralesionally (by injection) to a patient in need of such treatment, a sufficient amount of the purified human recombinant DNA alpha interferon, preferably recombinant DNA interferon alpha-2b, to be effective as an antitumor agent.

Claims

1. A method for treating human basal cell carcinoma comprising intralesionally administering to a human in need of such-treatment a sufficient amount of purified recombinant DNA human interferon alpha-2b to be effective as an anti-basal cell carcinoma agent.

2. A method of claim 1 wherein 13.5×

10⁶ I.U. of said interferon is administered during a three week period.

3. A method of claim 1 from 13.5×

10⁶ to 45×

10⁶ I.U. of said interferon is administered during a three week period.

4. A method of claim 1 wherein 16×

10⁶ I.U. of said interferon is administered during a three week period.